医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BIO Statement on Recent Developments in Japan’s Pharmaceutical Reimbursement and Pricing System

2016年11月23日 AM05:31
このエントリーをはてなブックマークに追加


 

WASHINGTON

Joseph Damond, Senior Vice President for International Affairs at the Biotechnology Innovation Organization (BIO), released the following statement in response to recent developments in Japan’s reimbursement and pricing system:

“As the world’s largest organization representing biotechnology innovators, including academic institutions, start-up enterprises, and biopharmaceutical companies of all sizes in more than 30 countries around the world, BIO regrets recent developments in Japan’s reimbursement and pricing system that make it less predictable and more risky for innovators.

“In recent years, BIO has praised initiatives in Japan that have improved its regulatory regime for new medicines as well as improved the climate for biotechnology research, development and innovation. Thus, it is disappointing to learn of recent instances of ad hoc decisions to modify prices of innovative medicines, which undermine the predictable and relatively stable rules-based system in place. BIO understands the fiscal pressures that contributed to these decisions, but believes that such issues should be treated in a holistic and deliberative manner, both to ensure that patients are not hurt by unintended consequences of decisions and that the progress Japan has made in improving incentives for biomedical research is not undermined.

“With other relevant stakeholders in Japan, BIO stands ready to work with the Government of Japan to help establish policies that promote public health and access to innovative medicines, while advancing the progress of biopharmaceutical innovation in Japan.”

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161122006065/en/

CONTACT

Biotechnology Innovation Organization
George Goodno, 202-962-6660
Web:
www.bio.org
Blog:
www.biotech-now.org
Twitter:
@IAmBiotech

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Premas与IncellDx签署印度经销协议
  • クリントン元大統領が第6回年次世界患者安全・科学・技術サミットで、病院における予防可能な死亡の根絶に傾注するヘルスケアリーダーらを相手に講演へ
  • 克林顿总统将在第6届世界患者安全科技峰会年会上面向医疗保健领袖发表演讲,重点是杜绝院内可预防死亡
  • Colorcon, Inc.以新推出的Opadry系统转变糖衣包膜工艺
  • AMR行业联盟的报告显示,生命科学行业正采取行动抗击抗微生物耐药,并有更多后续行动